Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Single-Dose, Parallel-Group Study Of The Pharmacokinetics And Safety Of Neratinib In Subjects With Chronic Hepatic Impairment And In Matched Healthy Adults

NCT00781430 is registered in ClinicalTrials.gov with Puma Biotechnology, Inc. as lead sponsor.

NCT NCT00781430
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00781430 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Single-Dose, Parallel-Group Study Of The Pharmacokinetics And Safety Of Neratinib In Subjects With Chronic Hepatic Impairment And In Matched Healthy Adults
Lead sponsor
Puma Biotechnology, Inc.
Phase
Phase 1
Overall status
Completed
Start date
April 30, 2009
Completion date
February 28, 2010
Enrollment
27 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatic insufficiency